Yuma Yamada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuma Yamada has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Hideyoshi Harashima
Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12 Nishi-6, Kita-ku, Sapporo 060-0812, Japan
61 shared publications Hideyoshi Harashima
48 shared publicationsYusuke Sato
Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
15 shared publications- Jiro Abe
Department of Pediatrics, Hokkaido University, Kita 15, Nishi 7, Sapporo 060-8638, Japan
14 shared publications Mitsue Hibino
11 shared publicationsEriko Kawamura
Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
10 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (20) , 1329
Solubilizer-Assisted Formulation of Porphyrin-Containing Lipid Nanoparticles for Photodynamic Applications
Hydrophobic porphyrin photosensitizers can lose photodynamic activity when densely loaded into nanoparticles because intermolecular aggregation promotes excited-state quenching. We investigated whether CAOM, a cinnamic-acid-derived oily solubilizer, could regulate the intraparticle organization of the π-extended porphyrin photosensitizer rTPA in MITO-Porter nanoparticles. Low-loading MITO-Porter (Low-MP), high-loading MITO-Porter (High-MP), and CAOM-containing High-MP (High-MP+CAOM) were prepared using the iLiNP microfluidic device. At an equivalent rTPA concentration, High-MP generated substantially less singlet oxygen than Low-MP, whereas High-MP+CAOM showed singlet oxygen generation comparable to Low-MP. High-MP+CAOM was internalized by HeLa cells and was observed in proximity to mitochondria. At comparable total lipid concentrations calculated from formulation inputs, High-MP+CAOM produced the greatest light-dependent reduction in cell viability, while dark toxicity remained limited under the tested conditions. Fluorescence spectroscopy was consistent with attenuated aggregation-caused quenching (ACQ), while cryo-transmission electron microscopy showed a more homogeneous intraparticle morphology after CAOM incorporation. These findings suggest that CAOM incorporation may support the photodynamic performance of porphyrin-containing lipid formulations under the tested conditions.
- 20 October 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (20) , 1329
Open AccessSolubilizer-Assisted Formulation of Porphyrin-Containing Lipid Nanoparticles for Photodynamic Applications
Hydrophobic porphyrin photosensitizers can lose photodynamic activity when densely loaded into nanoparticles because intermolecular aggregation promotes excited-state quenching. We investigated whether CAOM, a cinnamic-acid-derived oily solubilizer, could regulate the intraparticle organization of the π-extended porphyrin photosensitizer rTPA in MITO-Porter nanoparticles. Low-loading MITO-Porter (Low-MP), high-loading MITO-Porter (High-MP), and CAOM-containing High-MP (High-MP+CAOM) were prepared using the iLiNP microfluidic device. At an equivalent rTPA concentration, High-MP generated substantially less singlet oxygen than Low-MP, whereas High-MP+CAOM showed singlet oxygen generation comparable to Low-MP. High-MP+CAOM was internalized by HeLa cells and was observed in proximity to mitochondria. At comparable total lipid concentrations calculated from formulation inputs, High-MP+CAOM produced the greatest light-dependent reduction in cell viability, while dark toxicity remained limited under the tested conditions. Fluorescence spectroscopy was consistent with attenuated aggregation-caused quenching (ACQ), while cryo-transmission electron microscopy showed a more homogeneous intraparticle morphology after CAOM incorporation. These findings suggest that CAOM incorporation may support the photodynamic performance of porphyrin-containing lipid formulations under the tested conditions.
- Open Access
- 19 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
Trans MIT: microfluidically fabricated lipid nano capsules for robust intracellular delivery of mitochondria-derived components and metabolic enhancement
- 19 August 2026
- Published by Elsevier in Materials Today Advances
- Vol. 31
Open AccessTrans MIT: microfluidically fabricated lipid nano capsules for robust intracellular delivery of mitochondria-derived components and metabolic enhancement
- 16 May 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 699, 126988
Effect of vascular disrupting therapy by lipid nanoparticles on the tumor microenvironment
- 16 May 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 699, 126988
Effect of vascular disrupting therapy by lipid nanoparticles on the tumor microenvironment
- Open Access
- 23 April 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 628
Targeted Intracellular Delivery of Amino Acids to Trophoblast Cells Reveals Proteomic Signatures of Cellular Utilisation
Targeted delivery systems offer a promising approach for selectively modulating cellular processes; yet the intracellular consequences of targeted nutrient delivery to trophoblast cells remain poorly defined. Here, we investigated a previously validated placenta-targeting peptide conjugated to liposomes encapsulating stable isotope-labelled L-arginine and L-lysine to examine cellular uptake and downstream molecular responses in a trophoblast-like cell model. Peptide-dependent uptake of fluorescently labelled liposomes was confirmed in BeWo cells, demonstrating selective internalisation compared with non-targeted controls. Encapsulation of isotope-labelled amino acids enabled direct quantification of intracellular delivery and incorporation into the cellular proteome using stable isotope labelling by amino acids in cell culture (SILAC). Quantitative proteomic analysis revealed coordinated changes in proteins associated with translation, metabolism, and nitric oxide synthase regulation following targeted liposomal uptake. Notably, V-type proton ATPase subunit G1 (ATP6V1G1) and large neutral amino acid transporter small subunit 1 (SLC7A5) showed increased incorporation of labelled amino acids and were independently validated by Western blotting. Together, these findings establish a proof-of-concept platform for targeted intracellular amino acid delivery to trophoblast-like cells and define the resulting proteomic responses. This work provides mechanistic insight into intracellular amino acid utilisation and a framework for future studies in placental cell biology.
- 23 April 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (5) , 628
Open AccessTargeted Intracellular Delivery of Amino Acids to Trophoblast Cells Reveals Proteomic Signatures of Cellular Utilisation
Targeted delivery systems offer a promising approach for selectively modulating cellular processes; yet the intracellular consequences of targeted nutrient delivery to trophoblast cells remain poorly defined. Here, we investigated a previously validated placenta-targeting peptide conjugated to liposomes encapsulating stable isotope-labelled L-arginine and L-lysine to examine cellular uptake and downstream molecular responses in a trophoblast-like cell model. Peptide-dependent uptake of fluorescently labelled liposomes was confirmed in BeWo cells, demonstrating selective internalisation compared with non-targeted controls. Encapsulation of isotope-labelled amino acids enabled direct quantification of intracellular delivery and incorporation into the cellular proteome using stable isotope labelling by amino acids in cell culture (SILAC). Quantitative proteomic analysis revealed coordinated changes in proteins associated with translation, metabolism, and nitric oxide synthase regulation following targeted liposomal uptake. Notably, V-type proton ATPase subunit G1 (ATP6V1G1) and large neutral amino acid transporter small subunit 1 (SLC7A5) showed increased incorporation of labelled amino acids and were independently validated by Western blotting. Together, these findings establish a proof-of-concept platform for targeted intracellular amino acid delivery to trophoblast-like cells and define the resulting proteomic responses. This work provides mechanistic insight into intracellular amino acid utilisation and a framework for future studies in placental cell biology.
- 3 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 392, 114682
Mitochondria-targeted coenzyme Q10 nanocarriers evaluated by particle size and lipid composition alleviate early acetaminophen-induced liver injury
- 3 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 392, 114682
Mitochondria-targeted coenzyme Q10 nanocarriers evaluated by particle size and lipid composition alleviate early acetaminophen-induced liver injury
- Open Access
- 1 November 2025
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 48 (11) , 1652-1666
Mitochondrial Activation and Therapeutics: Innovations in Cell- and Organelle-Specific Medicine
Mitochondria are essential for cellular functions, including ATP production, calcium homeostasis, oxidative stress regulation, and apoptosis. Mitochondrial dysfunction is associated with a variety of diseases, including neurodegenerative disorders, skeletal muscle diseases, and mitochondrial diseases. This review explores the latest mitochondrial-targeted therapeutic approaches across the following key perspectives: (1) technological innovations in mitochondrial transplantation, focusing on tunnel nanotubes and extracellular vesicles; (2) the role of mitochondria in skeletal muscle diseases and therapeutic activation strategies; (3) advances in mitochondrial enhancement techniques within cell therapy, particularly in pediatric applications; and (4) the latest treatment modalities for mitochondrial diseases, such as gene and cell therapies. Taken together, these strategies demonstrate the transformative potential of mitochondrial targeting in cell- and organelle-specific medicine. Additionally, the MITO-Porter system is highlighted as an innovative drug delivery platform contributing to these advances.
- 1 November 2025
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 48 (11) , 1652-1666
Open AccessMitochondrial Activation and Therapeutics: Innovations in Cell- and Organelle-Specific Medicine
Mitochondria are essential for cellular functions, including ATP production, calcium homeostasis, oxidative stress regulation, and apoptosis. Mitochondrial dysfunction is associated with a variety of diseases, including neurodegenerative disorders, skeletal muscle diseases, and mitochondrial diseases. This review explores the latest mitochondrial-targeted therapeutic approaches across the following key perspectives: (1) technological innovations in mitochondrial transplantation, focusing on tunnel nanotubes and extracellular vesicles; (2) the role of mitochondria in skeletal muscle diseases and therapeutic activation strategies; (3) advances in mitochondrial enhancement techniques within cell therapy, particularly in pediatric applications; and (4) the latest treatment modalities for mitochondrial diseases, such as gene and cell therapies. Taken together, these strategies demonstrate the transformative potential of mitochondrial targeting in cell- and organelle-specific medicine. Additionally, the MITO-Porter system is highlighted as an innovative drug delivery platform contributing to these advances.
- Open Access
- 27 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (1) , 77-87
The effect of guide RNA thermal denaturation on the quality of Cas9 ribonucleoprotein-loaded lipid nanoparticle formulations
Gene-editing technology for the treatment of genetic diseases uses a system that delivers clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 as ribonucleoproteins (RNPs) in a faster and more transiently effective manner than other delivery methods that involve gene expression. Lipid nanoparticles (LNPs) are an integral part of technology that is used to deliver Cas9 RNPs, and in recent years the in vivo delivery of RNPs has been achieved. While single-guide RNA (sgRNA) forms complex higher-order structures, which are known to result in the formation of heterogeneous RNPs, the impact on RNP-loaded LNP formulations has been overlooked. The results of this study show that the heterogeneity of sgRNA significantly affects the internal structure, physical properties, and knockout activity of RNP-loaded LNP formulations through changes in molecular weight distribution and RNP charge.
- 27 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (1) , 77-87
Open AccessThe effect of guide RNA thermal denaturation on the quality of Cas9 ribonucleoprotein-loaded lipid nanoparticle formulations
Gene-editing technology for the treatment of genetic diseases uses a system that delivers clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 as ribonucleoproteins (RNPs) in a faster and more transiently effective manner than other delivery methods that involve gene expression. Lipid nanoparticles (LNPs) are an integral part of technology that is used to deliver Cas9 RNPs, and in recent years the in vivo delivery of RNPs has been achieved. While single-guide RNA (sgRNA) forms complex higher-order structures, which are known to result in the formation of heterogeneous RNPs, the impact on RNP-loaded LNP formulations has been overlooked. The results of this study show that the heterogeneity of sgRNA significantly affects the internal structure, physical properties, and knockout activity of RNP-loaded LNP formulations through changes in molecular weight distribution and RNP charge.
- Open Access
- 11 October 2025
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 48 (10) , 1533-1539
Mitochondrial Coenzyme Q10 Delivery Improves Energy Production in Rat Cardiac Myoblasts and Duchenne Muscular Dystrophy Model Rat Cardiomyocytes
Enhancing cardiomyocyte mitochondrial function has been reported as a potential therapeutic approach for various diseases. However, this is technically difficult, and its practical use has not been described. Although treatments such as exon skipping for skeletal muscle have been established for Duchenne muscular dystrophy (DMD), no curative treatment has been developed for DMD cardiomyopathy, and only cardioprotective medications and symptomatic treatments are available. In this study, we attempted to activate cardiac myocyte mitochondria via direct drug delivery using lipid nanoparticles and investigated the application of this strategy to diseased cells. First, we delivered CoQ10, a mitochondrial activator with cellular antioxidant capacity, into mitochondria in H9C2 cells using MITO-Porter, a mitochondria-directed nanoparticle. Cellular MITO-Porter uptake was measured using flow cytometry. Co-localization of mitochondria and MITO-Porter was confirmed using confocal laser microscopy. Mitochondrial respiratory capacity was measured using an extracellular flux analyzer. Furthermore, the concentration–response relationships of the amount of nanoparticles or CoQ10 with mitochondrial energy production capacity were confirmed. Next, we examined the possibility of improving mitochondrial energy production capacity in diseased cells. Cells were isolated from the myocardium of DMD model rats generated using the CRISPR-Cas9 system. Mitochondrial energy production capacity was lower in DMD primary cardiomyocytes than in wild-type primary cardiomyocytes. CoQ10 delivery to mitochondria in DMD primary cardiomyocytes using MITO-Porter improved mitochondrial energy production capacity. Thus, enhanced cardiomyocyte mitochondrial energy production might represent a potential treatment for cardiomyopathy.
- 11 October 2025
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 48 (10) , 1533-1539
Open AccessMitochondrial Coenzyme Q10 Delivery Improves Energy Production in Rat Cardiac Myoblasts and Duchenne Muscular Dystrophy Model Rat Cardiomyocytes
Enhancing cardiomyocyte mitochondrial function has been reported as a potential therapeutic approach for various diseases. However, this is technically difficult, and its practical use has not been described. Although treatments such as exon skipping for skeletal muscle have been established for Duchenne muscular dystrophy (DMD), no curative treatment has been developed for DMD cardiomyopathy, and only cardioprotective medications and symptomatic treatments are available. In this study, we attempted to activate cardiac myocyte mitochondria via direct drug delivery using lipid nanoparticles and investigated the application of this strategy to diseased cells. First, we delivered CoQ10, a mitochondrial activator with cellular antioxidant capacity, into mitochondria in H9C2 cells using MITO-Porter, a mitochondria-directed nanoparticle. Cellular MITO-Porter uptake was measured using flow cytometry. Co-localization of mitochondria and MITO-Porter was confirmed using confocal laser microscopy. Mitochondrial respiratory capacity was measured using an extracellular flux analyzer. Furthermore, the concentration–response relationships of the amount of nanoparticles or CoQ10 with mitochondrial energy production capacity were confirmed. Next, we examined the possibility of improving mitochondrial energy production capacity in diseased cells. Cells were isolated from the myocardium of DMD model rats generated using the CRISPR-Cas9 system. Mitochondrial energy production capacity was lower in DMD primary cardiomyocytes than in wild-type primary cardiomyocytes. CoQ10 delivery to mitochondria in DMD primary cardiomyocytes using MITO-Porter improved mitochondrial energy production capacity. Thus, enhanced cardiomyocyte mitochondrial energy production might represent a potential treatment for cardiomyopathy.
- Open Access
- 19 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Lipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G>T mutation in MtDNA (mt-Atp8)
Mitochondrial genome mutations are associated with various diseases and gene therapy targeted to mitochondria has the potential to effectively treat such diseases. Here, we targeted a point mutation in mitochondrial DNA (mtDNA) that can cause mitochondrial diseases via delivery of the clustered, regularly interspaced, short palindromic repeats/Cas9 (CRISPR/Cas9) system to mitochondria using an innovative lipid nanoparticle (LNP) delivery system. To overcome the major barrier of the mitochondrial membrane structure, we investigated a strategy to deliver ribonucleoprotein (RNP) directly to mitochondria via membrane fusion using MITO-Porter, a mitochondria-targeting lipid nanoparticle. First, we constructed RNP-MITO-Porter, in which an RNP was loaded into MITO-Porter using a microfluidic device. Sequence-specific double-strand breaks were confirmed when the constructed RNP-MITO-Porter was applied to isolated mitochondria. Next, the RNP-MITO-Porter was applied to HeLa cells, and a portion of the RNP-MITO-Porter was colocalized with mitochondria and caused sequence-specific double-strand breaks in mtDNA. Finally, RNP-MITO-Porter was successfully delivered to mitochondria of cells derived from a mouse carrying a point mutation (m.7778G > T) in mtDNA (mt-Atp8) (LMSF-N-MTFVB cells), and created double-strand breaks at the target sequence. RNP-MITO-Porter is expected to contribute significantly to the clinical application of mitochondrion-targeted gene therapy.
- 19 June 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessLipid nanoparticle delivery of the CRISPR/Cas9 system directly into the mitochondria of cells carrying m.7778G>T mutation in MtDNA (mt-Atp8)
Mitochondrial genome mutations are associated with various diseases and gene therapy targeted to mitochondria has the potential to effectively treat such diseases. Here, we targeted a point mutation in mitochondrial DNA (mtDNA) that can cause mitochondrial diseases via delivery of the clustered, regularly interspaced, short palindromic repeats/Cas9 (CRISPR/Cas9) system to mitochondria using an innovative lipid nanoparticle (LNP) delivery system. To overcome the major barrier of the mitochondrial membrane structure, we investigated a strategy to deliver ribonucleoprotein (RNP) directly to mitochondria via membrane fusion using MITO-Porter, a mitochondria-targeting lipid nanoparticle. First, we constructed RNP-MITO-Porter, in which an RNP was loaded into MITO-Porter using a microfluidic device. Sequence-specific double-strand breaks were confirmed when the constructed RNP-MITO-Porter was applied to isolated mitochondria. Next, the RNP-MITO-Porter was applied to HeLa cells, and a portion of the RNP-MITO-Porter was colocalized with mitochondria and caused sequence-specific double-strand breaks in mtDNA. Finally, RNP-MITO-Porter was successfully delivered to mitochondria of cells derived from a mouse carrying a point mutation (m.7778G > T) in mtDNA (mt-Atp8) (LMSF-N-MTFVB cells), and created double-strand breaks at the target sequence. RNP-MITO-Porter is expected to contribute significantly to the clinical application of mitochondrion-targeted gene therapy.